BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'COVID-19 Coronavirus'. (Return)

Yahoo BusinessAug 06, 2020
Goldman Says Covid-19 Vaccine Approval Could Upend Markets
(Bloomberg) -- Investors should consider the risk of a successful coronavirus vaccine unsettling markets by sparking a sell-off in bonds and rotation out of technology into cyclical stocks, according to Goldman Sachs Group Inc.The increased probability of an approved vaccine by the end of November is underpriced by equity markets, wrote strategists including Kamakshya Trivedi in a note Wednesday. Over the next few months, the ramifications of the U.S. election and the evolution of the virus -- in part as schools reopen -- are also likely to be key drivers of the market, they said.Approval of a vaccine could "challenge market assumptions both about cyclicality and about eternally negative real rates," the team wrote, adding such a scenario may support steeper yield curves, traditional cyclicals and banks, while challenging the leadership of technology stocks.If this happened along with a change in the U.S. administration, emerging market equities could benefit "if trade policy risks diminish while U.S. tax risks rise," according to the note.While the strategists suggested it may be too early for investors to position themselves aggressively for such a shift, they recommended options trades as a way to play the theme. For example, some call options on the S&P 500 still look attractive, and Goldman sees upside to around the 3,700 level should there be an early vaccine.That compares with a potential downside target of 2,200 should there be a significant reversal of activity from a second wave of the virus, the

Yahoo BusinessAug 05, 2020
Novavax signs COVID-19 vaccine supply deal with India's Serum Institute
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the "Pandemic Period" in all countries other than those designated by the World Bank as upper-middle or high-income countries. The deal was signed on July 30, according to an SEC filing by Novavax. On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.


Enterprise Application NewsJul 24, 2020
How AI helps scientists fight COVID-19
Artificial intelligence is useful for sorting through massive amounts of data and identifying anomalies within that data. Given the swaths of data healthcare workers and scientists are sorting through due to the coronavirus pandemic, Artificial intelligence and machine learning technologies have proven helpful in everything from predictive modeling to vaccine research and reading X-rays. InfoWorld senior writer Serdar Yegulalp joins Juliet to discuss how AI/ML tech is helping fight COVID-19 and how these technologies could be used by scientists, pharmaceutical companies and healthcare professionals alike in the future.

To read this article in full, please click here


TRENDING TAGS
TrumpFacebook coronavirus Post Twitter children
CoronavirusVaccine Trump Facebook latest immune
earningsCall Transcript Q2 Inc stock
StockMarket Earnings Gold Gains Futures
FacebookTrump Post children immune coronavirus
TikTokReels Instagram Facebook Launches Microsoft
CallEarnings Transcript Q2 Inc Corp
TranscriptEarnings Call Q2 Inc Corp
BillionTeladoc Health Livongo Airline Senators
Covid-19Vaccine App Apple Google Future

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC